Targeting the BMX in cancer: molecular mechanisms and emerging therapeutic strategies

2026-05-29

Man Zhang

Jinchi Chen

Rong Liang

Wei Jiang

Min Lin

Siqi Wen

Dejun Liu

Bei Yi

Ruiqi Chen

Tianyu Chen

Zhao Li *

DOI：10.1080/14756366.2026.2677282

Original

Original request for help

Save

Abstract

En 中文

Bone Marrow Tyrosine Kinase on Chromosome X (BMX), also known as epithelial/endothelial cell kinase (ETK), is a core member of the Tec family of non-receptor tyrosine kinases. Structurally, BMX kinase contains an N-terminal PH domain, a BH domain, a SH2 domain, a SH3 domain and a C-terminal catalytic tyrosine kinase domain. This distinctive modular architecture enables BMX to engage in diverse cellular signalling cascades. It has been reported that BMX is highly expressed and plays an oncogenic role in various cancers. In this paper, we mainly explore the function and mechanism of BMX in tumour cell proliferation, apoptosis, invasion, metastasis, cancer stem cell properties, angiogenesis and drug resistance. Furthermore, the research focus on summarising the research progress of BMX inhibitors for cancer treatment. This review aims to provide a theoretical framework for cancer therapy by targeting BMX.

Keywords:

BMX

proliferation

apoptosis

stemness

drug resistance

Targeting the BMX in cancer: molecular mechanisms and emerging therapeutic strategies

Abstract

Journal

Organization

Cited Papers

Citing Papers